The importance of prophylactic management of chemotherapy-induced neutropenia

Anti-Cancer Drugs

Volumn 14, Issue 9, 2003, Pages 725-730

  Repetto, Lazzaro ^a   Accettura, Caterina ^a  

^a INRCA   (Italy)

Author keywords

Chemotherapy; Colony stimulating factor; Granulocyte; Infection; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

CLINICAL TRIAL; DRUG DOSE REDUCTION; ECONOMIC ASPECT; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEALTH ECONOMICS; HUMAN; INFECTION; LEUKOCYTE COUNT; NEUTROPENIA; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR;

EID: 0242382818     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200310000-00006     Document Type: Review

References (41)

1. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998; 34:1857-1864.
2. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20:727-731.
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-340.
4. Meza L, Baselga J, Holmes FA, Liang B, Breddy J. Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 2002; 21: 255b (abstr 2840).
5. Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000; 36(suppl 1):S11-S14.
6. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558-3585.
7. ESMO. ESMO recommendations for the application of haematopoietic growth factors (hGFs). Ann Oncol 2001; 12:1219-1220.
8. Björkholm M, Ösby E, Hagberg H, et al. Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Blood 1999; 94(suppl 1):599a (abstr 2665).
9. Roy E, Smith RE, Brown AM, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999; 17:3403-3411.
10. Le Chevalier T, Monnier A, Douillard JY, et al. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 1998; 34:2032-2036.
11. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:164-170.
12. Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002; 9:203-211.
13. Agboola O, Crawford J, Dale DA, et al. Risk models for neutropenic complications associated with breast cancer adjuvant chemotherapy. Proc Am Soc Clin Oncol 2002; 21: 66a (abstr 261 and poster 261).
14. Gomez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 1998; 16:2065-2069.
15. Fortner B, Stolshek B, Tauer K, et al. Final analysis: chemotherapy-induced neutropenia (CIN) is associated with lower quality of life (QoL) in patients (pts) with cancer. Ann Oncol 2002; 13(suppl 5):174.
16. Calhoun E, Chang C-H, Welshman E, Cella D. A neutropenia-specific quality of life instrument: Rationale for the development of the FACT-N. Proc Am Soc Clin Oncol 2002; 21: 375a (abstr 1 498).
17. Bonadonna G, Valgussa P. Dose-response effect of chemotherapy in breast cancer. N Eng J Med 1981; 304:10-15.
18. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332:901-906.
19. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 1993; 4:651-656.
20. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80:1430-1436.
21. Leonard R, Miles D, Thomas R, Nussey F. The impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003; submitted.
22. Klastersky J. Current attitudes for therapy of febrile neutropenia with consideration to cost effectiveness. Curr Opin Oncol 1998; 10:284-290.
23. Kerr K. The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemother 1999; 44:587-591.
24. Dale D. Management of febrile neutropenia: the shift from treatment to prevention. Oncol Spectrums 2002; 3:6-7.
25. Bodey G, Elting L, Kassamali H, Lim B. Escherichia coli bacteria in cancer patients. Am J Med 1986; 81:85-95.
26. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 293:319-324.
27. de Graaf H, Willemse PH, Bong SB, et al. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 1996; 53:289-294.
28. Cappozzo C. Predicting the risk of neutropenic complications in patients treated with adjuvant chemotherapy for early-stage breast cancer. Presented at the 27th Annual ONS Congress, Washington, DC, 2002.
29. Lyman GH, Crawford J, Dale D, et al. Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy. Proc Am Soc Clin Oncol 2001; 20: 349a (abstr 1571).
30. Lyman GH, Morrison VA, Dale D, et al. Risk of first febrile neutropenia (FN) among patients receiving CHOP chemotherapy. Proc Am Soc Clin Oncol 2002; 21: 358a (abstr 1430).
31. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998; 16:2392-2400.
32. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymph 2000; 37:351-360.
33. Voog E, Bienvenu J, Warzocha K, et al. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumour necrosis factor ligand-receptor system. J Clin Oncol 2000; 18:325-331.
34. Weiner N, Fridman M, Steinberg D, et al. A model to predict chemotherapy-related neutropenic events in intermediate and high grade lymphoma (IHL) patients (PTS). Blood 1998; 92(suppl 1): 88a (abstr 361).
35. Croockewit AJ, Bronchud MH, Aapro MS, et al. A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. Eur J Cancer 1997; 33:1732-1746.
36. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology 2000; 14:221-227.
37. Kuderer N, Cosler L, Crawford J, Dale D, Lyman G. Cost and mortality associated with febrile neutropenia in adult cancer patients. Proc Am Soc Clin Oncol 2002; 21: 250a (abstr 998).
38. Cosler L, Agboola O, Calhoun E, Lyman G. An updated risk threshold model for G-CSF prophylaxis use in cancer chemotherapy: Incorporation of patient out-of-pocket and indirect costs. Presented at the 7th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, 2002.
39. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18:2522-2528.
40. Green MD, Koelbl H, Baselga J, et al. A randomized, double-blind, phase 3 study of fixed-dose, single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14:29-35.
41. Siena S, Piccart M, Holmes FA, Glaspy J, Hackett J, Renwick J. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003; 10:715-724.